Products are for professional/laboratory use only. We are pleased to announce the launch of the new Vircell AmpliRun® that contains the purified RNA of SARS-CoV-2 B.1.1.7 lineage, also known as VOC 202012/01 or UK variant, to be used as a control in nucleic acid amplification-based techniques.
Products are for professional/laboratory use only. We are happy to announce the launch of new Vircell Transport Medium (TM) for the collection and preservation of viruses.
Products are for professional/laboratory use only.
AccuPlex™ Reference Material Kits are designed to measure day-to-day performance of the assay, providing both a positive and a negative reference solution.
Being the third¹ liquid biopsy test for Biocartis, the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
Get connected and enjoy the advantages of Idylla Explore, a web-based application that allows you to analyze your data by providing:
A revolution in liquid biopsy cancer research.
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Biocartis is pleased to announce the publication of an important study  by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.